Sickle cell gene therapies face slow uptake
CNBC · RSS · · AI-summarised by FinFlash
FDA-approved gene therapies for sickle cell disease offer a chance to help patients, but cost and access factors have slowed their use. The treatments remain difficult for many patients to obtain despite regulatory clearance. For investors, the gap between approval and real-world uptake signals that commercial returns from these therapies may take longer to materialize than the initial enthusiasm suggested.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.